Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Liabilities: 2021-2025

Historic Total Liabilities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $225.1 million.

  • ARS Pharmaceuticals' Total Liabilities rose 1254.44% to $225.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.1 million, marking a year-over-year increase of 1254.44%. This contributed to the annual value of $94.4 million for FY2024, which is 3786.12% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Total Liabilities stood at $225.1 million, which was up 85.84% from $121.2 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Total Liabilities ranged from a high of $225.1 million in Q3 2025 and a low of $2.4 million during Q4 2023.
  • Over the past 3 years, ARS Pharmaceuticals' median Total Liabilities value was $11.3 million (recorded in 2023), while the average stood at $54.5 million.
  • In the last 5 years, ARS Pharmaceuticals' Total Liabilities slumped by 80.47% in 2022 and then skyrocketed by 3,786.12% in 2024.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Total Liabilities stood at $16.7 million in 2021, then crashed by 48.73% to $8.5 million in 2022, then tumbled by 71.60% to $2.4 million in 2023, then soared by 3,786.12% to $94.4 million in 2024, then skyrocketed by 1,254.44% to $225.1 million in 2025.
  • Its Total Liabilities stands at $225.1 million for Q3 2025, versus $121.2 million for Q2 2025 and $98.3 million for Q1 2025.